

Kajian HPMRS syor tambahbaik sistem penjagaan rawatan kanser

DAILY EXPRESS

3 MAY 2012

KUALA LUMPUR: Kajian mengenai Sistem Laporan Pengurusan dan Prestasi Penjagaan Kesihatan (HPMRS) sedang dijalankan bagi menyediakan satu syor standard kepada kerajaan bagi menambahbaik perkhidmatan sistem penjagaan rawatan kanser di hospital.

Kajian penting ini juga diharap dapat menyediakan maklumat penting yang membenarkan penggubal dasar menilai matlamat menggerakkan perubahan dasar untuk kualiti penjagaan yang lebih baik, kata Penyiasat Prinsipal bagi projek HPMRS Dr Lim Teck Onn.

Kajian ini akan memberi perhatian terhadap onkologi secara umum dan kajian awal mengenai barah payu dara diikuti barah paru-paru dan penyakit kanser berkaitan, katanya kepada pemberita di Kuching, Sarawak.

"Kami berharap kajian itu akan menjawab satu set soalan utama, berkisar daripada tahap penyakit kepada akses rawatan dan selepas

diagnosis," katanya.

"Kajian HPMRS juga melihat kepada kadar survival antara satu dan lima tahun, dan ia menterjemahkan kepada berapa lama pesakit-pesakit barah payu dara hidup sebaik mereka didiagnos," kata Dr Lim, yang juga bekas pengarah Pusat Penyelidikan Klinikal (CRC) di Hospital Kuala Lumpur.

Dr Lim juga berkata masanya telah tiba bagi syarikat-syarikat penjagaan kesihatan supaya mempertimbang dengan serius bagi memperkenalkan langkah-langkah prestasi dan belajar untuk menuntut lebih daripada sekadar laporan daripada pengurus-pengurus mereka.

Kajian tiga tahun itu dijangka berakhir pada 2013 dan disokong oleh Roche (Malaysia) Sdn. Bhd. Hasil kajian yang dikemaskini itu akan dikemukakan setiap enam bulan, katanya. - Bernama

You are here: >> Bernama News

CANCER CARE IN MALAYSIA: TOWARDS QUALITY PERFORMANCE

Date: 02-05-2012

CANCER CARE IN MALAYSIA...(repeat)

The performance of the cancer care system in Malaysia is under scrutiny. The landmark Healthcare Performance and Management Report System (HPMRS) study will help identify what works and what does not. And that will help policy decisions too.

KUCHING, May 2 (Bernama) -- A Healthcare Performance and Management Report System (HPMRS) study is underway to provide the Malaysian government with recommendation for the increased use of performance measurement and reporting for purposes of accountability and population health. The research protocol of the HPMRS has been reviewed and approved by the Ministry of Health's Research & Ethics Committee, paving the way for clinical groups and healthcare providers to participate in the first ever program of its kind that aims to promote improvement in the delivery of care to patients.

Oncology is a key focus area, and the HPMRS for Breast Cancer hopes to provide a standard measurement for cancer department of hospitals in Malaysia (government and private).

A set of key questions that we hope to answer are as follows, Firstly, in terms of disease staging - do Malaysian breast cancer patients present early or late, and what types of breast cancer do they present with? Secondly, it looks at timely access to treatment post diagnosis, how long do patients have to wait for the appropriate treatment? Finally, the HPMRS study looks at 1 and 5 year survival rates which simply translate to how long do Malaysian breast cancer patients live once they have been diagnosed? explained Dr. Lim Teck Onn, the former director of the Clinical Research Centre (CRC) at Hospital Kuala Lumpur (HKL), who is one of the Principal Investigators of the HPMRS project.

It is hoped that the results of the HPMRS study will help identify opportunities where healthcare professionals can pursue quality improvement, in cancer care and also provide valuable information that allows policy makers to evaluate with the aim of mobilizing policy change for better quality care.

Although significant gains have been made in both the prevention and treatment of cancer, many Malaysians do not receive the evidence-based intervention, such as screenings and adjuvant therapies, that are known to be effective in the early diagnosis and subsequent management of their disease, said Dr Arni Talib, Pathologist at HKL.

Clearly, with a maturing healthcare sector, the time has come for Malaysian healthcare companies to seriously consider introducing performance measures. The Board of Management of these companies must learn to demand more than just financial reports from their managers, not to mention the potential value of superior performance measure for marketing purpose and to differentiate one self from the competition, elaborated Dr. Lim.

This study involves the active participation of representatives from across the spectrum of healthcare stakeholders, and is guided by a Committee comprised of experts from the cancer community, as well as others with expertise in performance measurement. Its Principal Investigators are Dr Gerard Lim (Head of Oncology Department, HKL), Dr Lim Teck Onn (former director of CRC), Dato Dr Mohamed Ibrahim A. Wahid (President of Malaysian Oncological Society), Professor Yip Cheng Har (Breast Surgeon, University Malaya Medical Centre) and Dr Arni Talib (Pathologist, HKL).

The 3 year study is expected to conclude in 2013 and is supported by Roche (Malaysia) Sdn. Bhd. An update of the study results will be presented every 6 months.

About HPMRS

Founded in 2010 by Yun Consulting, ClinData & Stats Consult, HPMRS is designed to help healthcare industry implement routine healthcare performance measurement

and reporting. It provides a complete one-stop solution including measurement protocol, on-line data submission, independent third party data audit, statistical reports & publishing. Healthcare providers measure performance for variety of reasons such as to comply with regulation or JCI accreditation, to meet the demands of healthcare payers or the requirement, of Health Tourism Council; but ultimately through rigorous and transparent performance measurement and reporting, HPMRS is meant to promote healthcare accountability and to improve the delivery of care for our population health. Managed by a total of 5 professionals comprising health researcher, data managers and statisticians, HPRMS is committed to their core business of health research and delivering excellent client service. For more information, please visit www.hprms.com.my

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80 000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com

SOURCE: Roche (M) Sdn Bhd

FOR MORE INFORMATION CONTACT:

Name : Lynn Wong Abdullah
Media Relations
Mobile: +6012 2980579
Email : poh_lyn.wong@roche.com

--BERNAMA